Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis

医学 羟甲唑啉 上睑下垂 随机对照试验 安慰剂 视力 临床终点 麻醉 外科 眼科 内科学 肾上腺素能受体 病理 受体 替代医学
作者
Charles B. Slonim,Shane Foster,Mark Jaros,Shane Kannarr,Michael S Korenfeld,Robert Smyth-Medina,David Wirta
出处
期刊:JAMA Ophthalmology [American Medical Association]
卷期号:138 (11): 1168-1168 被引量:16
标识
DOI:10.1001/jamaophthalmol.2020.3812
摘要

Importance

Treatment of acquired blepharoptosis (ptosis) is currently limited to surgical intervention.

Objective

To examine the efficacy and safety of oxymetazoline hydrochloride, 0.1%, ophthalmic solution (oxymetazoline, 0.1%) in participants with acquired ptosis.

Design, Setting, and Participants

This pooled analysis of 2 randomized, double-masked, placebo-controlled, multicenter phase 3 clinical trials included participants 9 years and older with acquired ptosis and superior visual field deficit. The 2 studies were conducted across 16 and 27 sites in the United States. Patients were enrolled from May 2015 to April 2019. Analyses for the individual trials were initiated after database lock and completed on September 6, 2017, and May 16, 2019. Pooled analysis was completed on August 25, 2019.

Interventions

Participants (randomized 2:1) received oxymetazoline, 0.1%, or vehicle, self-administered as a single drop per eye, once daily, for 42 days.

Main Outcomes and Measures

The primary efficacy end point was change from baseline in the number of points seen on the Leicester Peripheral Field Test, a test to detect superior visual field deficits due to ptosis, on days 1 (6 hours after instillation) and 14 (2 hours after instillation). The secondary end point, change from baseline in marginal reflex distance 1, was assessed at the same time points.

Results

In total, 304 participants were enrolled (mean [SD] age, 63.8 [13.8] years; 222 women [73%]). Overall, 97.5% (198 of 203) of participants receiving oxymetazoline, 0.1%, and 97.0% (98 of 101) of participants receiving vehicle completed the studies. Oxymetazoline, 0.1%, was associated with a significant increase in the mean (SD) number of points seen on the Leicester Peripheral Field Test vs vehicle (day 1: 5.9 [6.4] vs 1.8 [4.1]; mean difference, 4.07 [95% CI, 2.74-5.39];P < .001; day 14: 7.1 [5.9] vs 2.4 [5.5]; mean difference, 4.74 [95% CI, 3.43-6.04];P < .001). Oxymetazoline, 0.1%, also was associated with a significant increase in marginal reflex distance 1 from baseline (mean [SD]: day 1: 0.96 [0.89] mm vs 0.50 [0.81] mm; mean difference, 0.47 mm [95% CI, 0.27-0.67];P < .001; day 14: 1.16 [0.87] mm vs 0.50 [0.80] mm; mean difference, 0.67 mm [95% CI, 0.46-0.88];P < .001). Treatment-emergent adverse events (TEAEs) occurred in 31.0% (63 of 203) of participants receiving oxymetazoline, 0.1%, and 35.6% (36 of 101) of participants receiving vehicle. Among participants receiving oxymetazoline, 0.1%, with a TEAE, 81% (51 of 63) had a maximum TEAE intensity of mild, and 62% (39 of 63) had no TEAE suspected of being treatment related.

Conclusions and Relevance

Oxymetazoline, 0.1%, was associated with positive outcomes and was well tolerated in phase 3 trials after instillation at days 1 and 14, demonstrating its potential promise for the treatment of acquired ptosis, although further study is needed to elucidate the clinical relevance of these findings beyond 6 weeks.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Rondab应助机灵枕头采纳,获得10
6秒前
佳无夜完成签到,获得积分10
11秒前
摆哥完成签到,获得积分10
15秒前
66完成签到,获得积分10
20秒前
zlqq完成签到 ,获得积分10
20秒前
Hardskills发布了新的文献求助10
23秒前
24秒前
之_ZH完成签到 ,获得积分10
32秒前
gds2021完成签到 ,获得积分10
34秒前
你好呀嘻嘻完成签到 ,获得积分10
34秒前
梅特卡夫完成签到,获得积分10
36秒前
熊雅完成签到,获得积分10
37秒前
39秒前
睡到自然醒完成签到 ,获得积分10
40秒前
cis2014完成签到,获得积分10
42秒前
独特的大有完成签到 ,获得积分10
42秒前
量子星尘发布了新的文献求助10
43秒前
45秒前
xingyi完成签到,获得积分10
47秒前
48秒前
舒心的秋荷完成签到 ,获得积分10
51秒前
zz123发布了新的文献求助10
52秒前
liaomr完成签到 ,获得积分10
52秒前
粗犷的灵松完成签到,获得积分10
53秒前
吃小孩的妖怪完成签到 ,获得积分10
53秒前
ncuwzq完成签到,获得积分10
55秒前
yshj完成签到 ,获得积分10
56秒前
58秒前
净禅完成签到 ,获得积分10
1分钟前
1分钟前
迷人的寒风完成签到,获得积分10
1分钟前
1分钟前
water应助科研通管家采纳,获得10
1分钟前
Lucas应助HHHAN采纳,获得10
1分钟前
无情修杰完成签到 ,获得积分10
1分钟前
小柒完成签到 ,获得积分10
1分钟前
聪慧芷巧发布了新的文献求助10
1分钟前
1分钟前
1分钟前
蓝意完成签到,获得积分0
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022